Report overview
The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS).AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive.
This report aims to provide a comprehensive presentation of the global market for Human Immunodeficiency Virus (HIV)-1 Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Immunodeficiency Virus (HIV)-1 Therapeutics. This report contains market size and forecasts of Human Immunodeficiency Virus (HIV)-1 Therapeutics in global, including the following market information:
Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Human Immunodeficiency Virus (HIV)-1 Therapeutics market was valued at US$ 12220 million in 2022 and is projected to reach US$ 12890 million by 2029, at a CAGR of 0.8% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.
We surveyed the Human Immunodeficiency Virus (HIV)-1 Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Segment Percentages, by Type, 2022 (%)
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists
Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Labs
Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Human Immunodeficiency Virus (HIV)-1 Therapeutics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Human Immunodeficiency Virus (HIV)-1 Therapeutics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie, Inc.(U.S.)
Merck & Co., Inc. (U.S.)
Bristol-Myers Squibb Company (U.S.)
Boehringer Ingelheim GmbH (Germany)
Genentech, Inc. (U.S.)
Cipla, Inc. (India)
Outline of Major Chapters:
Chapter 1: Introduces the definition of Human Immunodeficiency Virus (HIV)-1 Therapeutics, market overview.
Chapter 2: Global Human Immunodeficiency Virus (HIV)-1 Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Human Immunodeficiency Virus (HIV)-1 Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Human Immunodeficiency Virus (HIV)-1 Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
